- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00423176
The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)
February 7, 2022 updated by: Organon and Co
Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis
The purpose of this study is to evaluate the efficacy and safety of Nasonex® (mometasone furoate nasal spray), when used together with an antibiotic, for the relief of symptoms associated with acute bacterial sinusitis.
Efficacy will be based on both subjective (assessment of symptom severity by the patient) and objective measurements (computed tomography [CT] imaging of the sinuses).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
237
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be 12 years of age and older, of either sex, and of any race.
- Must weigh at least 40 kg (88 lb).
- Must be willing to give written informed consent and be able to adhere to dose and visit schedules.
- Must have a clinical diagnosis of acute bacterial sinusitis.
- Must be symptomatic at the Screening and Baseline Visits on the basis of subject assessments of major symptoms score.
- Must have radiographic evidence of sinusitis on CT scans taken at Screening.
- Must be in general good health and free of any clinically significant disease (other than sinusitis) that would interfere with the study schedule or procedures, or compromise the subject's safety.
- A subject's clinical laboratory tests (hematology, blood chemistry, and urinalysis), vital signs, and electrocardiogram (ECG) recordings must be within normal limits or clinically acceptable to the investigator/qualified designee. Any test results that are questionable should be referred to the sponsor.
- A female subject of child-bearing potential must have a negative serum pregnancy (beta-hCG) test at Screening. She must agree to use a medically accepted method of contraception throughout the entire study period. Postmenopausal women will be exempted from the use of contraception during the study. Documented absence of menses for at least 1 year will indicate that a female is postmenopausal. If a pre-menarche female subject begins menstruating during the study, a serum pregnancy test must be done at the next visit. A female subject of child-bearing potential who is not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the study.
Exclusion Criteria:
- A subject with moderate to severe persistent asthma that requires daily treatment with inhaled steroids, or an exacerbation of asthma within the past 30 days.
- A history of chronic sinusitis (symptoms lasting greater than 3 months) or having undergone sinus or nasal surgery for chronic sinusitis or nasal polyps.
- A history of symptomatic seasonal allergic rhinitis and who, during the study period, is living in or traveling to locations where the allergen to which he/she is allergic is present.
- Subject with glaucoma or a history of posterior subcapsular cataracts.
- Subject with nasal polyps visible upon physical examination, immotile cilia syndrome, immunodeficiency disease, cystic fibrosis, clinically significant cardiovascular (including rheumatic heart disease), pulmonary, renal, hepatic, metabolic, hematological or neurologic disease that in the investigator's judgment might interfere with the evaluation of the therapy, or subjects who are immunocompromised, in renal failure, or on dialysis.
- Subject fails to observe the medication washout times outlined in the protocol prior to Screening.
- Subject has an allergy to corticosteroids or penicillins.
- Subject has used any investigational drug within 30 days of Screening.
- Subject has a concurrent need for antibiotic therapy other than study drug (amoxicillin/clavulanic acid).
- Subject is anticipating sinus or nasal surgery within the next month.
- Subject has been previously randomized into this study.
- Subject is part of the staff personnel directly involved with the study or is a family member of the investigational study staff involved in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MFNS + Antibiotic
Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic.
Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
|
MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Other Names:
|
Placebo Comparator: Placebo
Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
|
Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Change in AM/PM PRIOR Major Symptoms Score (Mss) Minus Sinus Headache Averaged Over Days 1 to 29.
Time Frame: 29-day Treatment Period and 2-week no-treatment Follow-up Period.
|
The least squares mean decrease from Baseline in AM/PM PRIOR MSS, excluding sinus headache, averaged over Days 1 to 29.
PRIOR is the subject's status over the previous 12 hours (reflective).
The MSS was defined as the sum of the following subject-evaluated symptoms: facial pain/pressure/tenderness, sinus headache, purulent rhinorrhea, post-nasal drip, and nasal stuffiness/congestion.MSS scores are as follows: 0=none, 1=mild, 2=moderate, 3=severe for each individual symptom.
|
29-day Treatment Period and 2-week no-treatment Follow-up Period.
|
Change From Baseline to Endpoint in Percent of Opacification of the Maxillary Sinus That Had the Maximum Opacification Score at Baseline
Time Frame: 29-day Treatment Period and 2-week no-treatment Follow-up Period.
|
A coronal computerized tomography was obtained to visulaize all nasal sinuses and the ostiomeatal complex.
Opacification was measured as a percentage of the area of the sinus that was occupied by either fluid or mucosal thickening.
The change in percentage of opacification of one maxillary sinus (the one with the highest percentage of opacification) as compared to antibiotic treatment alone.
The percentage of opacification was measured and the change from baseline for that percentage was reported.
|
29-day Treatment Period and 2-week no-treatment Follow-up Period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
January 17, 2007
First Submitted That Met QC Criteria
January 17, 2007
First Posted (Estimate)
January 18, 2007
Study Record Updates
Last Update Posted (Actual)
February 16, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P04824
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
St. Louis UniversityTerminatedStent | Sinusitis, FrontalUnited States
-
Oulu University HospitalTampere University HospitalRecruitingSinusitis | Maxillary Sinusitis | Sinusitis, AcuteFinland
-
Cairo UniversityNot yet recruitingChronic Maxillary Sinusitis
-
Centre Hospitalier Intercommunal CreteilActive, not recruitingChronic Maxillary SinusitisFrance
-
DeyCompletedACUTE SINUSITISUnited States
Clinical Trials on MFNS and antibiotic
-
Organon and CoCompleted
-
Organon and CoIntegrated Therapeutics GroupCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoQuintiles, Inc.Completed
-
Mahidol UniversityCompletedBacteriuria | Kidney Transplantation | Asymptomatic InfectionsThailand
-
The Cleveland ClinicCompletedOveractive Bladder | Urge Incontinence | Urinary Incontinence, Urge | Overactive Bladder SyndromeUnited States
-
Insmed IncorporatedRecruitingChronic Rhinosinusitis Without Nasal PolypsUnited States, Australia, Argentina, Canada
-
Organon and CoCompleted
-
Organon and CoCompleted